NCT00375648 2017-06-02
TRAPEZE
Novartis
Phase 3 Completed
Clinical Trials
19 trialsNCT00219271 2017-05-31
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Novartis
Phase 4 Completed
NCT00172055 2017-03-06
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
Novartis
Phase 3 Completed
NCT00171639 2017-02-23
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
Novartis
Phase 3 Completed
NCT00237146 2017-02-23
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Novartis
Phase 4 Completed
NCT00242554 2017-02-23
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Novartis
Phase 4 Completed
NCT00434317 2017-02-23
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00334139 2017-02-07
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Novartis
Phase 4 Completed
NCT00391690 2016-11-18
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Novartis
Phase 4 Completed
NCT00242567 2014-05-07
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Phase 3 Completed
NCT00005073 2013-05-01
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
Novartis
Phase 3 Terminated
NCT00172016 2012-04-30
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Novartis
Phase 4 Completed
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00258765 2010-04-26
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
Novartis
Phase 2 Terminated
NCT00035997 2009-11-23
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Novartis
Phase 4 Completed
NCT00087659 2009-11-23
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
Novartis
Phase NA Completed
NCT00391950 2009-11-23
Maintaining Bone Strength in Men With Prostate Cancer
Novartis
Phase 3 Terminated
NCT00636740 2009-02-20
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Merrion Pharmaceuticals, LLC
Phase 2 Completed
NCT00072930 2008-01-15
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
MedImmune LLC
Phase 2 Completed